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Summary: Purpose: A 34-year-old woman with progressive 
myoclonus epilepsy of Unverricht-Lundborg type was consid- 
ered for vagus nerve stimulation (VNS) therapy. 
Methods: After demonstration of intractability to multiple 
antiepileptic regimens and progressive deterioration in cerebel- 
lar function, the patient was implanted with a vagus nerve 
stimulator and followed for 1 year. Neurological status, seizure 
frequency, and parameter changes were analyzed. 
Results: VNS therapy resulted in reduction of seizures (more 
than 90%) and a significant improvement in cerebellar function 
demonstrated on neurological examination. The patient re- 
ported improved quality of life based in part on her ability to 
perform activities of daily living. 
Conclusions: VNS therapy may be considered a treatment 
option for progressive myoclonus epilepsy. The effects of VNS 
on seizure control and cerebellar dysfunction may provide 
clues to the underlying mechanism(s) of action. Key Words: 
Vagus nerve-Progressive myoclonus epilepsy-Electrical 
stimulation-Epilepsy-Seizure. 
Progressive myoclonus epilepsy of Unverricht- 
Lundborg type (PME-UL) is a rare, autosomal recessive 
disorder characterized by spontaneous, stimulus- 
sensitive, and action myoclonus, tonic-clonic seizures, 
and cerebellar dysfunction (ataxia, dysarthria, tremor). 
Age of onset is usually in childhood, and the disease 
course is variable, ranging from limitations in perform- 
ing activities of daily living to complete incapacitation. 
Dementia is usually mild and occurs late in the course of 
the disease (1). 
Using linkage analysis, Lehesjoki et al. (2) identified 
the gene locus for PME-UL (EPM1) on chromosome 21, 
band q22.3. The EPMl gene has been associated with a 
gene encoding a cysteine protease inhibitor, cystatin B 
(3). The specific mechanism whereby one gene abnor- 
mality allows development of typical clinical and neu- 
ropathological features has not been determined. Treat- 
ment of PME-UL typically consists of antiepileptic 
drugs, usually in polytherapy regimens. Valproic acid 
(VPA), clonazepam, and phenobarbital (PB) have pro- 
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duced symptomatic benefit, but phenytoin (PHT) has led 
to progressive deterioration (4). Reduced seizure fre- 
quency and improved neurological function have also 
been reported in EPMl patients treated with piracetam 
( 5 ) ,  zonisamide (ZNS) (6), baclofen (7), and 
N-acetylcysteine, a sulfhydryl antioxidant (8). 
Vagus nerve stimulation (VNS) reduces seizure fre- 
quency in some patients with intractable localization- 
related epilepsy (9). We report a case in which a patient 
with PME-UL had improved seizure control and reduced 
cerebellar dysfunction after implantation of a vagus 
nerve stimulator. 
CASE REPORT 
The patient was a 34-year-old woman of Finnish de- 
scent who developed myoclonus at age 12 years. She had 
her first generalized tonic-clonic seizure 2 years later. 
Her paternal great grandfather had a history of seizures, 
but the clinical semiology and nature of the illness were 
unknown. There were no other risk factors for seizures 
or epilepsy. 
The patient was initially diagnosed as having primary 
generalized epilepsy. Electroencephalograms revealed 
bursts of bilaterally synchronous 2.5- to 4-Hz spike/ 
1046 
VNS AND PROGRESSIVE MYOCLONUS EPILEPSY 1047 
slow-wave and polyspike/slow-wave discharges, which 
were activated by photic stimulation. She was treated 
with various antiepileptic drugs (AEDs), including PHT, 
PB, VPA, and clonazepam, either alone or in com- 
bination. Treatment with PHT worsened her myoclonus 
and tremor. Later, she developed impaired cognition, 
tremor, and dysarthria, and a diagnosis of progressive 
myoclonus epilepsy was made 12 years after the first 
symptoms appeared. 
The patient had focal, regional, and generalized my- 
oclonus, which occurred on an almost daily basis. Pre- 
cipitants included video games, stress, and laughter. 
Clustering of seizures coincided with stress, alcohol use, 
use of oral contraceptives, and singing at parties. When 
attempts were made to simplify her AED regimen, dete- 
rioration resulting from increased myoclonus led to dif- 
ficulties performing activities of daily living, including 
drinking from a cup and washing dishes. 
Generalized tonic-clonic seizures usually lasting 2 to 3 
minutes occurred every 2 to 3 months. Secondary inju- 
ries included a fractured nose (three times), periorbital 
trauma, and fractures of the teeth and ribs. 
Physical examination revealed a pleasant young 
woman with mild flattening of affect, monoprosody, 
bradyphrenia, and drowsiness. She had moderately se- 
vere ataxic dysarthria characterized by explosive, hesi- 
tant, and staccato articulation with long pauses for word 
finding and a slow speech rate. Extraocular movements 
were conjugately full but contaminated by square wave 
jerks. There was mild ptosis bilaterally as well as fine 
eyelid and mouth tremors. 
Tremor involved most muscle groups and was aggra- 
vated by postural input or action. Myoclonus appeared 
intermittently at rest. Both upper extremities exhibited 
decreased tone with suspension. There was mild 
polyminimyoclonus of the fingers (ataxic type), more 
prominent on the right. Moderate ataxia was present in 
the arms and legs, and Romberg’s sign was present. Gait 
was widely based, mildly stooped, and moderately 
slowed. There was loss of hand and arm swing, in- 
ability to perform tandem gait, and a tendency to turn en 
bloc. Reflexes were increased bilaterally in a symmet- 
ric distribution. 
Magnetic resonance imaging of the brain showed at- 
rophy of the brachium pontis and the inferior aspect of 
the cerebellum. Muscle biopsy and evoked potential 
studies were normal. 
Genetic testing confirmed the diagnosis of PME-UL 
by demonstrating the most common mutation, an expan- 
sion in the promoter of the cystatin B gene, by Southern 
blot analysis (PstI) as well as low levels of cystatin B 
messenger RNA. 
Despite the use of various AEDs, the patient continued 
to have frequent seizures and progressive cerebellar dys- 
function with occasional secondary injury. Her most re- 
cent regimen included clonazepam 8 mg/d, VPA 1,750 
mg/d, PB 45 mg/d, and lamotrigine (LTG) 200 mg/d. 
Attempts to obtain piracetam and ZNS were unsuccess- 
ful. Discussion of other potential treatment options, in- 
cluding VNS, surfaced at this time. It was explained to 
the patient that the vagus nerve stimulator was approved 
for use in partial epilepsy and that there was anecdotal 
evidence of benefit in primary and secondary generalized 
epilepsies, although there was no known experience with 
its use in PME-UL. 
A vagus nerve stimulator (Cyberonics; Houston, 
Texas, U.S.A.) was implanted in December 1998, and 
indicators were set at minimal levels (Table l),  as is 
customary in our program. Within 3 weeks of implanta- 
tion, the patient returned to the clinic and reported no 
appreciable change. Parameter changes were made, in- 
cluding maintenance of a narrow pulse bandwidth (130 
microseconds), increasing the current (0.5 mA), and in- 
creasing overall stimulation time (on time, 30 seconds; 
off time, 10 minutes). We based these conservative 
changes on our previous experience with improved tol- 
erability at lower pulse bandwidths (130 to 250 micro- 
seconds) and lack of previous reported experience with 
vagal stimulation in this syndrome. The changes resulted 
in a dramatic improvement. The patient reported no sei- 
zures, and physical examination demonstrated reduction 
of tremor, dysarthria, and ataxia. Polyminimyoclonus 
with arms outstretched was barely perceptible, and over- 
all tremulousness of limbs, eyelids, and mouth was simi- 
larly reduced. Although her affect remained restricted, 
her speech showed more prosodic variation, a higher rate 
of word production per minute without hesitation, less 
staccato and explosive articulation, and almost normal 
overall understandability. Bradyphrenia decreased, and 
no drowsiness appeared during the interview. Her gait 
improved to a narrowly based walk, still with restricted 
arm and head swing and stooped posture, but overall she 
moved at a faster rate. She still turned en bloc. No my- 
oclonus appeared at rest. Limb ataxia on finger-to-nose 
TABLE 1. VNS parameter settings 
Operating 
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settings change change change 
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testing was mild. She attended multiple parties and fam- 
ily functions without exacerbation. No changes in her 
antiepileptic medications or VNS parameter settings 
were made for 5 months after her initial clinic visit. 
Although the patient continued to be free of seizures, 
we considered the possibility of obtaining further im- 
provement with increasing stimulation indicators. Soon 
after these changes (Table l), the patient had her only 
generalized seizure in 6 months, but her daily function- 
ing was improved significantly. 
About 9 months after implantation, the patient noted a 
slight increase in breakthrough seizures and worsening 
of cerebellar dysfunction. She appeared to be developing 
a tolerance to the effects of the stimulation. The final 
indicator changes were made (current, 1 .O mA; on time, 
30 seconds; off time, 3 minutes), and the patient returned 
to the level of improvement she had noted earlier in the 
course of stimulation. No changes in her antiepileptic 
drug regimen of clonazepam, VPA, PB, and LTG have 
been made since vagus nerve stimulator implantation. 
DISCUSSION 
VNS is effective at reducing seizures in patients with 
intractable partial seizures. More recently, some patients 
with symptomatic generalized epilepsy have also shown 
significant seizure reduction (1 0). Our patient with PME- 
UL also benefited from VNS with marked seizure reduc- 
tion and improvement in cerebellar abnormalities (i.e., 
reduction in ataxia, tremor, and dysarthria). 
Possible mechanisms by which VNS reduces seizure 
frequency have been reviewed by McLachlan (1 1). Fa- 
vorable outcomes in a small number of patients with 
PME-UL after treatment with piracetam ( 5 )  and 
N-acetylcysteine (8) raise questions about the underlying 
abnormality in PME-UL and potential treatment options. 
Although we are cautious about drawing conclusions 
from a single case report with limited follow-up, the 
dramatic improvement shown by our patient in both re- 
duced seizures and overall neurological status requires 
further study. Although the response seen in this patient 
is likely attributable to symptomatic relief as opposed to 
direct effects on the underlying disease process, it nev- 
ertheless had a very beneficial influence on overall qual- 
ity of life. This positive tandem response for both seizure 
control and sensorimotor function in a patient with PME- 
UL may help clarify the biochemical effects produced 
by chronic vagus stimulation. VNS may be a treat- 
ment option for patients frequently refractory to AED 
polytherapy, and it may also provide further insight 
into the motor and cognitive pathophysiology of this ge- 
netic abnormality. 
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